Patient-, disease-, and transplant-related characteristics
| Variable . | Cell dose . | P . | |||
|---|---|---|---|---|---|
| N . | ≤3.0 × 108 cells/kg . | N . | >3.0 × 108 cells/kg . | ||
| Number of patients | 50 | 50 | |||
| Disease type | 50 | 50 | .48 | ||
| AML | 21 (42) | 27 (54) | |||
| ALL | 14 (28) | 11 (22) | |||
| CML | 15 (30) | 12 (24) | |||
| Disease stage before transplantation | 50 | 50 | .07 | ||
| Early | 38 (76) | 27 (54) | |||
| Intermediate | 8 (16) | 16 (32) | |||
| Advanced | 4 (8) | 7 (14) | |||
| Male sex | 50 | 36 (72) | 50 | 22 (44) | .01 |
| Age at transplantation, years | 50 | 27 (5-59) | 50 | 26 (5-59) | .81 |
| Year of transplantation | 50 | 50 | .32 | ||
| 1985-1988 | 25 (50) | 20 (40) | |||
| 1989-1994 | 25 (50) | 30 (60) | |||
| Conditioning regimen | 50 | 50 | .83 | ||
| BuCY ± other | 18 (36) | 17 (34) | |||
| CyTBI ± other | 32 (64) | 33 (66) | |||
| Patient CMV-positive | 45 | 22 (49) | 44 | 20 (45) | .75 |
| Donor CMV-positive | 44 | 18 (41) | 42 | 16 (38) | .79 |
| Karnofsky score, ≤80% | 50 | 8 (16) | 50 | 10 (20) | .60 |
| WBC at diagnosis | 46 | 18 (1-371) | 45 | 24 (1-490) | .24 |
| Neutrophil >0.5 × 109/L, median, days | 49 | 17 (9-34) | 46 | 14 (8-52) | .32* |
| Platelets >25 × 109/L, median, days | 50 | 23 (0-85) | 43 | 18 (5-248) | .15* |
| Acute GVHD | 50 | 49 | .51 | ||
| None | 46 (92) | 43 (88) | |||
| Grade I | 3 (8) | 2 (4) | |||
| Grade II | 1 (2) | 3 (6) | |||
| Grade III | 0 (0) | 1 (2) | |||
| Chronic GVHD | 48 | 48 | .21 | ||
| None | 48 (100) | 45 (94) | |||
| Limited | 0 (0) | 3 (6) | |||
| Median follow-up, months | 77.4 | 74.6 | .22* | ||
| Variable . | Cell dose . | P . | |||
|---|---|---|---|---|---|
| N . | ≤3.0 × 108 cells/kg . | N . | >3.0 × 108 cells/kg . | ||
| Number of patients | 50 | 50 | |||
| Disease type | 50 | 50 | .48 | ||
| AML | 21 (42) | 27 (54) | |||
| ALL | 14 (28) | 11 (22) | |||
| CML | 15 (30) | 12 (24) | |||
| Disease stage before transplantation | 50 | 50 | .07 | ||
| Early | 38 (76) | 27 (54) | |||
| Intermediate | 8 (16) | 16 (32) | |||
| Advanced | 4 (8) | 7 (14) | |||
| Male sex | 50 | 36 (72) | 50 | 22 (44) | .01 |
| Age at transplantation, years | 50 | 27 (5-59) | 50 | 26 (5-59) | .81 |
| Year of transplantation | 50 | 50 | .32 | ||
| 1985-1988 | 25 (50) | 20 (40) | |||
| 1989-1994 | 25 (50) | 30 (60) | |||
| Conditioning regimen | 50 | 50 | .83 | ||
| BuCY ± other | 18 (36) | 17 (34) | |||
| CyTBI ± other | 32 (64) | 33 (66) | |||
| Patient CMV-positive | 45 | 22 (49) | 44 | 20 (45) | .75 |
| Donor CMV-positive | 44 | 18 (41) | 42 | 16 (38) | .79 |
| Karnofsky score, ≤80% | 50 | 8 (16) | 50 | 10 (20) | .60 |
| WBC at diagnosis | 46 | 18 (1-371) | 45 | 24 (1-490) | .24 |
| Neutrophil >0.5 × 109/L, median, days | 49 | 17 (9-34) | 46 | 14 (8-52) | .32* |
| Platelets >25 × 109/L, median, days | 50 | 23 (0-85) | 43 | 18 (5-248) | .15* |
| Acute GVHD | 50 | 49 | .51 | ||
| None | 46 (92) | 43 (88) | |||
| Grade I | 3 (8) | 2 (4) | |||
| Grade II | 1 (2) | 3 (6) | |||
| Grade III | 0 (0) | 1 (2) | |||
| Chronic GVHD | 48 | 48 | .21 | ||
| None | 48 (100) | 45 (94) | |||
| Limited | 0 (0) | 3 (6) | |||
| Median follow-up, months | 77.4 | 74.6 | .22* | ||
Log-rank test.
AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; TX, transplant; Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradiation; CMV, cytomegalovirus; WBC, white blood cells; DX, diagnosis; GVHD, graft-versus-host disease.